{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:46:09Z","timestamp":1770911169967,"version":"3.50.1"},"reference-count":15,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2023,5,30]]},"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1183\/13993003.00865-2023","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T16:45:43Z","timestamp":1688748343000},"page":"2300865","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice"],"prefix":"10.1183","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-0388","authenticated-orcid":false,"given":"Scott H.","family":"Donaldson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"2024102012313312000_62.1.2300865.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73469"},{"key":"2024102012313312000_62.1.2300865.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043891"},{"key":"2024102012313312000_62.1.2300865.3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jcf.2018.01.001","article-title":"Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"key":"2024102012313312000_62.1.2300865.4","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jcf.2020.07.009","article-title":"A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: effect on mucociliary clearance and clinical outcomes","volume":"19","author":"Donaldson","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024102012313312000_62.1.2300865.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02652-2017"},{"key":"2024102012313312000_62.1.2300865.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043900"},{"key":"2024102012313312000_62.1.2300865.7","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206716"},{"key":"2024102012313312000_62.1.2300865.8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(09)60105-3","article-title":"Relationship between pulmonary exacerbations and lung function decline in a 6\u2005month trial of denufosol","volume":"8","author":"Accurso","year":"2009","journal-title":"J Cystic Fibrosis"},{"key":"2024102012313312000_62.1.2300865.9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S2213-2600(21)00546-4","article-title":"The effect of inhaled hypertonic saline on lung structure in children aged 3-6\u2005years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial","volume":"10","author":"Tiddens","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102012313312000_62.1.2300865.10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","article-title":"Preventive inhalation of hypertonic saline in infants with cystic fibrosis (PRESIS). A randomized, double-blind, controlled study","volume":"199","author":"Stahl","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102012313312000_62.1.2300865.11","unstructured":"Cystic Fibrosis Foundation Patient Registry. Annual Data Report. Cystic Fibrosis Foundation, Bethesda, 2021."},{"key":"2024102012313312000_62.1.2300865.12","doi-asserted-by":"publisher","DOI":"10.1136\/thx.52.10.900"},{"key":"2024102012313312000_62.1.2300865.13","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0050OC"},{"key":"2024102012313312000_62.1.2300865.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00960-2021"},{"key":"2024102012313312000_62.1.2300865.15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00865-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:14:54Z","timestamp":1740381294000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00865-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,7]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1183\/13993003.00865-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00865-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}